We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rare Gene Variants Doubles Alzheimer's Disease Risk

By LabMedica International staff writers
Posted on 26 Dec 2013
Variations in a gene have been identified that doubles a person's risk of developing Alzheimer's disease later in life. More...


A number of common genetic variants have been linked to early-onset, which strikes before age 65, and the more common late-onset forms of Alzheimer's disease, but those variants account for only a fraction of Alzheimer's cases.

A team led by scientists at the Washington University School of Medicine (St. Louis, MO, USA) analyzed DNA from people in families in which multiple members were affected by Alzheimer's disease. They sequenced all the protein-coding genes from several individuals in each of 14 families, using a technique called whole exome sequencing. Some of these family members had an Alzheimer's diagnosis, but others did not.

After the initial exome sequencing, the team used more detailed sequencing to look closely at the phospholipase-D 3 (PLD3) gene in another 4,000 people of the same age, some of whom had Alzheimer's disease. This study helped them identify additional variants in the gene that increased risk for Alzheimer's, indicating that the PLD3 gene clearly had a role in the development of late-onset Alzheimer's disease.

Additional analyses conducted in the laboratory showed that when the PLD3 gene is active, levels of amyloid-beta decline. This substance aggregates in the brains of Alzheimer's patients to form plaques. When the scientists decreased expression of PLD3, levels of amyloid-beta increased.

Carlos Cruchaga, PhD, the lead author of the study, said, “We were very excited to be able to identify a gene that contains some of these rare variants and we were surprised to find that the effect of the gene was so large. After adjusting for other factors that can influence risk for the disease, we found that people with certain gene variants were twice as likely as those who didn't have the variants to develop Alzheimer's. We studied 11,000 other people with and without the disease and found that a PLD3 gene variant doubled the risk for Alzheimer's disease.” The study was published on December 11, 2013, in the journal Nature.

Related Links:

Washington University School of Medicine






Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gastrointestinal Panel
Xpert® GI Panel
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.